lutetium has been researched along with Disease Exacerbation in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J | 1 |
| Akhurst, T; Eu, P; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Jackson, P; Kong, G; Murphy, DG; Ravi Kumar, A; Sandhu, S; Scalzo, M; Thang, SP; Violet, J; Williams, SG | 1 |
| Berntzen, DT; Løitegård, T; Thiis-Evensen, E | 1 |
| Blanksby, A; Crumbaker, M; Emmett, L; Epstein, R; Eu, P; Gedye, C; Guminski, A; Ho, B; Horvath, L; Joshua, AM; Mahon, K; Ratnayake, L; Stricker, P; Willowson, K; Yin, C | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA | 1 |
| Głowa, B; Hubalewska-Dydejczyk, AB; Jabrocka-Hybel, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pach, D; Pawlak, D; Sowa-Staszczak, A; Stefańska, A; Tomaszuk, M; Trofimiuk, M | 1 |
| Boerman, OC; Boers-Sonderen, MJ; Desar, IM; Langenhuijsen, JF; Mulders, PF; Oosterwijk, E; Oyen, WJ; Smith-Jones, PM; Stillebroer, AB; van Herpen, CM | 1 |
| Arunachalam, T; Bogdan, NJ; Cappelletti, E; Chen, J; Eaton, SM; Feng, W; Fox, JS; Lantry, LE; Lattuada, L; Linder, KE; Maddalena, ME; Metcalfe, EC; Nunn, AD; Raju, N; Reubi, JC; Swenson, RE; Thomas, R; Tweedle, MF | 1 |
| Bakker, WH; de Herder, WW; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
| Alvarez, RD; Austin, M; Grizzle, WE; Khazaeli, MB; Kilgore, L; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J | 1 |
4 trial(s) available for lutetium and Disease Exacerbation
| Article | Year |
|---|---|
[
Topics: Aged; Dipeptides; Disease Progression; Health Status; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Time Factors; Treatment Outcome; Victoria | 2018 |
Results of a Prospective Phase 2 Pilot Trial of
Topics: Aged; Aged, 80 and over; Dipeptides; Disease Progression; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Image Processing, Computer-Assisted; Lutetium; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Rate | 2019 |
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Radiation; Female; Humans; Immunoconjugates; Kidney Neoplasms; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Netherlands; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Time Factors; Tissue Distribution; Treatment Outcome; Tumor Burden; Whole Body Imaging | 2013 |
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Arthralgia; Bone Marrow; Disease Progression; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intraperitoneal; Lutetium; Middle Aged; Ovarian Neoplasms; Platelet Count; Radioimmunotherapy; Radioisotopes | 1997 |
7 other study(ies) available for lutetium and Disease Exacerbation
| Article | Year |
|---|---|
Lutetium oxodotreotide (
Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms | 2021 |
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Topics: Aged; Diagnostic Imaging; Disease Progression; Female; Humans; Lutetium; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Receptors, Peptide; Statistics, Nonparametric; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2012 |
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
Topics: Animals; Binding, Competitive; Bombesin; Cell Line, Tumor; Disease Progression; Gene Expression Regulation; Humans; Lutetium; Male; Mice; Mice, Nude; Oligopeptides; Peptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin | 2006 |
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
Topics: Adult; Aged; Bronchial Neoplasms; Carcinoid Tumor; Disease Progression; Female; Humans; Lutetium; Male; Medical Oncology; Middle Aged; Octreotide; Peptides; Radioisotopes; Remission Induction; Stomach Neoplasms; Thymus Neoplasms; Treatment Outcome | 2007 |